Chemical Biology & Drug Design

Cover image for Vol. 86 Issue 6

Edited By: David Selwood

Impact Factor: 2.485

ISI Journal Citation Reports © Ranking: 2014: 28/59 (Chemistry Medicinal); 164/290 (Biochemistry & Molecular Biology)

Online ISSN: 1747-0285

Author Guidelines

Aims and scope

Types of paper

Reviews and perspectives

Research Articles

Research Letters


Online submission

Initial submission

Submission of a revised manuscript

Guidelines for Research Article Manuscript Preparation
Title page
Methods and Materials
Conclusions Acknowledgements
Conflict of Interest
Figure Legends and Tables
Supporting Information
Graphical Table of Contents

Guidelines for Research Letter Manuscript Preparation

Guidelines for ‘Review’ and ‘Perspective’ Manuscript Preparation

Guidelines for Describing Chemical, Biological, Drug Design and Related Experimental Information

Page Charges

Copyright Transfer Agreement Form

Post Acceptance Procedures
Accepted Articles
Early View
Author material archive policy
Note to NIH Grantees
Production tracking

Aims and Scope

 Chemical Biology & Drug Design is a peer-reviewed scientific journal that is dedicated to the advancement of innovative science, technology and medicine with a focus on the multidisciplinary fields of chemical biology and drug design. It is the aim of Chemical Biology & Drug Design to capture significant research and drug discovery that highlights new concepts, insight and new findings within the scope of chemical biology and drug design.


The following scientific topics will exemplify the scope of the journal:

·        Protein, peptide, peptidomimetic, nucleic acid, lipids, carbohydrate and natural product chemical biology and drug design

·        Receptor agonist/antagonist, protease substrate/inhibitor, and signal transduction modulator chemical biology and drug design

·        Small-molecule diversity and synthetic methods important to investigate chemical space relationships to drug discovery

·        Structure-based drug design, molecular modeling.

·        Virtual screening of drug targets and related in silico chemoinformatics and bioinformatics technologies

·        NMR, X-ray crystallography, calorimetry and related biophysical technologies

·        Therapeutic target proteomics, chemical genomics and molecular screening technologies

·        Emerging chemical, biological and drug design concepts of significance to pharmacology, ADMET and drug delivery

·        Novel proof-of-concept ligands and breakthrough medicines (CB&DD thematic issues)


Types of paper

Chemical Biology & Drug Design welcomes correspondence in the following categories:

·        Reviews and perspectives will be focused on a significantly important theme to chemical biology and drug design. Reviews should incorporate a judicious use of tables, figures, schemes and references. Perspectives are short reviews on a narrow topic.

·        Research Articles will provide detailed description of scientific findings within the scope of the journal and formatted according to guidance highlighted below with respect to subheadings, inclusion of tables and/or figures, reference style, etc.

·        Research Letters will be short version of a Research Article, but should be continuous text (subheadings for 'Results and Discussion' and 'Conclusions and Future Directions' are optional).

·        Commentaries will be invited by the Editors to provide focused viewpoints of specific topics of interest, and written as continuous text with no subheadings.



To submit a manuscript for Chemical Biology & Drug Design please visit
If you have any problems with the electronic submission, please contact Andrea
Lewis at the central Editorial Office:


Initial submission
At initial submission, we encourage authors to submit their text, figures and tables as one PDF file for the purposes of peer review. Alternatively the following files will be converted into a single PDF:

·        The manuscript (including title page, abstract, main text, references and tables) in Word format.

·        Figures can be included with the main text for reviewing purposes, or provided as a Powerpoint or PDF file.

·        Supplementary figures and tables for publication should be included for reviewing purposes (see Supplementary material).

Please note that high quality images in the correct format for Production will be required should your manuscript be accepted.


Submission of a revised manuscript
Please follow instructions in the revision letter provided in the editorial decision letter. You will need to:

·        Provide a point-by-point response to the reviewers’ comments online.

·        Upload a revised version of the text in Word format.

·        Upload separate print quality figure files in TIFF or EPS format. Information on our digital illustration standards can be obtained here:


Guidelines for Research Article Manuscript Preparation

Articles should be assembled as below:


Title page

Should include the following:

·        Title- less than 50 words

·        short running title - less than 50 characters,

·        5-10 keywords,

·        complete names of institutions for each author, and the name, address, phone number, fax number and e-mail address for the corresponding author.


Abstract: Less than 200 words. Abstracts should include a sentence that clarifies the novelty of the manuscript and its place in the field. No references may be included in the abstract.

Introduction: Should be focused; exhaustive literature overviews are not appropriate.

Methods and Materials: Must contain sufficient detail such that, in combination with the references cited, all experiments reported can be fully reproduced. “Nested” methods are not acceptable.

Results should be kept distinct from the discussion.

Discussion: This section discusses and interprets the results with regard to the previous work in the field and as reported in the literature.

Conclusions Acknowledgments: All sources of institutional, private and corporate financial support for the work within the manuscript must be fully acknowledged.

Conflict of Interest: All authors must declare financial/commercial conflicts of interest, or declare if there is none,

References should be cited in the text parenthetically by number, listed at the end of the manuscript in the order cited. “In press” references or “personal communication” are not permitted. CB&DD uses the Vancouver style of references that is outlined below. In all cases, the author list should be abbreviated to et al. after 15 authors.

Journal Article
1. Sawyer, T.K. (2004) Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin Investig Drugs 13: 1-19.

Article in Book
2. Sawyer, T.K. (1997) Peptidomimetic and nonpeptide drug discovery: Impact structure-based drug design. In: Veerapandian, P., editor. Structure-Based Drug Design: Diseases, Targets, Techniques and Developments. Marcel Dekker, New York, USA, p. 559-634.

Complete Book
3. Borchardt, R.T., Freidinger, R.M., Sawyer, T.K., Smith, P.L. (1998) Integration of Pharmaceutical Discovery and Development: Case Histories. Plenum Publishing Corp., New York, USA.

We recommend the use of a tool such as
EndNote or Reference Manager for reference management and formatting. 

  Notes should be listed in the text as superscript lower case letters, a, b, c, etc and listed at the end of the manuscript (following the References section) in the order cited in the text. Websites should also be listed in the Notes section and not within the reference list. Other usage of the Notes section may be permitted as dependent on editorial review.

Abbreviations: The use of unnecessary abbreviations is strongly discouraged. CB&DD adheres to the conventions outlined in Units, Symbols and Abbreviations: A guide for medical and scientific editors and authors. Non-standard abbreviations must be used 5 or more times and written in full when first used.


Figures: All figures should be planned to fit within either 1 column width (8 cm), 1.5 column widths (13 cm) or 2 column widths (17 cm), and must be suitable for photocopy reproduction from the typeset version of the manuscript. These should be at a resolution of at least 300 dpi at final size.

The editors recommend using the detailed guidelines

If preferred, authors may submit figures and schemes in PDF format on submission. However, please note that TIFF or EPS files will be requested should the manuscript be accepted.

Chemical structures should be prepared using a chemical drawing program (e.g., ChemDraw) as standard practice and saved as TIFF or EPS files in submitting along with Tables and manuscript (text and references).


Figure Legends and Tables should be a separate section of the manuscript. Tables should be double spaced with no vertical rulings, with a single bold ruling beneath the column titles. Units of measurement must be included in the column title.


Supporting Information: The availability of Supporting Information should be indicated in the main manuscript by a paragraph, to appear after the References, headed 'Supporting Information' and providing titles of figures, tables, etc. The Supporting Information should be submitted in its final form. No changes can be made subsequently by the Editorial Office or the Publisher. When submitting Supporting Information via the electronic submission website authors should choose ‘Supplementary File’ from the file designation drop down list on the File Upload page. Further details on Supporting Information are available here.

In general, Supplemental Information is limited to data and other materials that directly support the main conclusions of a paper but are considered additional or secondary support for the main conclusions, or cannot be included in the main paper for reasons such as space or file format restrictions. Supplemental Information should be within the conceptual scope of the main paper and not extend beyond it. The quality and presentation of Supplemental Information should be on par with that in the main paper and is subject to the same scientific standards.

Please note it is not acceptable to move material from the main paper to Supporting Information to avoid page charges.


Graphical Table of Contents

CBDD’s table of contents will be presented in graphical form with a brief abstract.

graphical table of contents

The table of contents entry must include the article title, the authors' names (with the corresponding author indicated by an asterisk), no more than 80 words or 3 sentences of text summarising the key findings presented in the paper and a figure that best represents the scope of the paper. Table of contents entries should be submitted to ScholarOne, uploaded as ‘Graphical Abstract’ during the manuscript submission process.

The image should be supplied as a tif or a pdf and fit within the dimensions of 50mm x 60mm, and be fully legible at this size.

CB & DD publishes in English.  Non-native speakers are advised to have their manuscripts checked for grammar and style by a native English speaker before submission. A list of independent suppliers of editing services can be found here. All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication.

Guidelines for Research Letter Manuscript Preparation

The same as Research Articles with the exception that headings are not required and Letters are no more than 4 typeset pages in length. There are no page charges for Letters.

Guidelines for ‘Review’ and ‘Perspective’ Manuscript Preparation

These are the same as for Research Articles, but without a methods section. Sub-headings can be used as required.

Guidelines for Describing Chemical, Biological, Drug Design and Related Experimental Information

Chemical (and Related) Experimental Information.Chemical reactions should be shown for synthetic transformations of significance to the theme of the manuscript. The chemical name and compound number should be described within the Methods and Materials for each compound synthesized in those manuscripts focused, in part, on chemistry. Purity and proof-of-structure criteria of synthetic compounds should be described as well as methods.  In general 1H and 13C NMR, CHN or high resolution MS and HPLC data are required. For manuscripts having significant amounts of such data, it is recommended that the Supplementary Information option be considered to an appropriate extent. For compound libraries, general characterization of the libraries and more detailed analysis of specific molecules from the libraries should be considered with respect to purity and proof-of-structure criteria.  Biological (and Related) Experimental Information. Biological testing must be described in sufficient detail for all key molecules highlighted in the manuscript (i.e., lead compounds). Biological testing methods and materials must be described in sufficient details to enable others to repeat such work. Screening hits reported are required to have the structure verified by supporting analyses (NMR and LCMS). The source of bacterial strains and cell lines should be provided.

 Statistical analysis for biological data should be provided in most circumstances. Doses and concentrations of drug samples should be expressed in typical units such as mg/kg or mol/kg.

Drug Design (and Related) Experimental Information. Drug design and related computational, chemoinformatics, and structural biology experimental methods must be detailed with appropriate references to both hardware and software used. For macromolecular structures , authors must deposit the atomic coordinates with the Protein Data Bank at Rutgers University (, and the file name provided in the manuscript (i.e., at the end of the abstract AND as a reference/footnote). The co-ordinates must be uploaded with this initial submission so available for review and publication. Co-ordinates are also required for homology models at submission. Programs (software) used for drug design should be described with inclusion of the commercial source if appropriate. Detailed description of complex molecular modelling studies (i.e., conformational calculations) should be provided.

No responsibility is assumed by the journal or editors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material published herein.


Original research papers are supposed to be no longer than 7 full typeset pages. In the event of a paper being longer, the Publisher will charge 100 USD per extra page to the author. Authors need to approve these costs upon submission of their paper in ScholarOne Manuscripts. Each typeset page can roughly be estimated to contain approximately 750 words, 2 or 3 Figures or Tables, or 50 references. PLEASE NOTE THAT THIS IS ONLY AN APPROXIMATE GUIDE.

Invited reviews have no page charges. Uninvited reviews should be limited to 20 pages. If additional pages are required, there will be a charge to the authors of 100 USD per extra page. There are no charges for colour figures.

Copyright Transfer Agreement Form
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions

For authors choosing OnlineOpen If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution License OAA

Creative Commons Attribution Non-Commercial License OAA

Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services and visit

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit:


Accepted Articles
Articles in this journal which have been peer-reviewed and accepted, but not yet copy-edited, are published online through our Accepted Articles feature in advance of publication in print. This service has been designed to ensure the earliest possible circulation of research papers immediately after acceptance, and as such will not be checked or corrected in any way. Readers should note that articles published within Accepted Articles have been fully refereed, but have not been through the copy-editing and proof corrections process, or amended to journal style. Graphics are placed at the end of the PDF and may be compressed to reduce download time of the PDF. Once the manuscript has been through the production process (approximately 30 days) the article is removed from the accepted articles area and published as normal.

Proofs should be returned with the least possible delay and with only essential corrections. Authors will be required to pay for any major alterations from their original manuscripts, and it may sometimes be necessary to disallow excessive changes.
The corresponding author will receive an email alert containing a link to a web site. A working e-mail address must therefore be provided for the corresponding author. The proof can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the following web site:
This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Further instructions will be sent with the proof.


Free access to the final PDF offprint of your article will be available via author services only. Please therefore sign up for author services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers. Paper offprints of the printed published article may be purchased if ordered via the method stipulated on the instrons that will accompany the proofs. Printed offprints are posted to the correspondence address given for the paper unless a different address is specified when ordered. Note that it is not uncommon for printed offprints to take up to eight weeks to arrive after publication of the journal. For order enquiries please email:

Early View
Chemical Biology & Drug Design is covered by our Early View service. Early View articles are complete full-text articles published online in advance of their issue publication. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found on the Web:

Author material archive policy
Please note that unless specifically requested, Wiley-Blackwell will dispose of all hardcopy or electronic material submitted two months after publication. If you require the return of any material submitted, please inform the editorial office or production editor as soon as possible if you have not yet done so.

Note to NIH Grantees
Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see


OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see
Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website at:

Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

The copyright statement for OnlineOpen authors will read:
© [date] The Author(s)
Journal compilation © [date] Blackwell Munksgaard

Online production tracking is now available for your article through Wiley-Blackwell's Author Services.
Author Services enables authors to track their article – once it has been accepted – through the production process to publication online. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The author will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.